AU2001236005A1 - Preparations stabilized over long time - Google Patents

Preparations stabilized over long time

Info

Publication number
AU2001236005A1
AU2001236005A1 AU2001236005A AU3600501A AU2001236005A1 AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1 AU 2001236005 A AU2001236005 A AU 2001236005A AU 3600501 A AU3600501 A AU 3600501A AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1
Authority
AU
Australia
Prior art keywords
long time
over long
stabilized over
preparations stabilized
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236005A
Other languages
English (en)
Inventor
Akihiko Saito
Yasushi Sato
Tadao Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001236005A1 publication Critical patent/AU2001236005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001236005A 2000-02-29 2001-02-28 Preparations stabilized over long time Abandoned AU2001236005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000053310 2000-02-29
JP2000-53310 2000-02-29
PCT/JP2001/001524 WO2001064241A1 (fr) 2000-02-29 2001-02-28 Preparations stabilisees a long terme

Publications (1)

Publication Number Publication Date
AU2001236005A1 true AU2001236005A1 (en) 2001-09-12

Family

ID=18574710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236005A Abandoned AU2001236005A1 (en) 2000-02-29 2001-02-28 Preparations stabilized over long time

Country Status (5)

Country Link
US (1) US7163671B2 (fr)
EP (1) EP1260230A4 (fr)
JP (1) JP4683810B2 (fr)
AU (1) AU2001236005A1 (fr)
WO (1) WO2001064241A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
BRPI0110914B8 (pt) * 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
CA2774959C (fr) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Methode d'utilisation de dicetopiperazines et composition contenant ces substances
DE60229961D1 (de) * 2001-08-29 2009-01-02 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol
EP1541165A4 (fr) * 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Methode de stabilisation de preparations de solution de proteines
KR20050089857A (ko) * 2002-12-26 2005-09-08 아지노모토 가부시키가이샤 간암 발생 및 진행 억제제
CN103191409A (zh) 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
JP4253688B2 (ja) * 2006-11-30 2009-04-15 三洋化成工業株式会社 凍結乾燥用保護剤及び生理活性物質の製造方法
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP4812807B2 (ja) * 2007-06-27 2011-11-09 三洋化成工業株式会社 タンパク質含有水溶液安定化剤及びタンパク質含有水溶液の安定化方法
PT2197919E (pt) 2007-08-27 2014-07-17 Ratiopharm Gmbh Formulação líquida de conjugado de g-csf
EP3381445B1 (fr) * 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
CA2710418A1 (fr) 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Formulations de peptides et de proteines stabilisees
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
CN103599541A (zh) * 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
EP2542257B1 (fr) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
CN104958752B (zh) 2011-10-10 2019-01-18 安皮奥制药股份有限公司 退行性关节病的治疗
JP6231484B2 (ja) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 鼻炎の処置
EP2825548A4 (fr) 2012-03-14 2016-02-24 Yeda Res & Dev Peptides de kisspeptine modifiés et leurs utilisations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
SG10201705525VA (en) * 2013-03-13 2017-08-30 Genentech Inc Formulations with reduced oxidation
KR20150132508A (ko) 2013-03-15 2015-11-25 앰피오 파마슈티컬스 인코퍼레이티드 줄기세포의 가동화, 회귀, 증식 및 분화를 위한 조성물 및 이의 사용 방법
KR20170045274A (ko) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 관절 징후의 치료
CN107106585B (zh) * 2015-02-06 2021-01-01 杭州美南医药科技有限公司 万古霉素的水溶液制剂
EP3310375A4 (fr) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies
RS62832B1 (sr) * 2016-05-27 2022-02-28 Ipsen Biopharm Ltd Tečna neurotoksin formulacija stabilizovana sa triptofanom ili tirozinom

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56154419A (en) 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JP2577742B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JP2577743B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
JPH02116515A (ja) 1988-10-26 1990-05-01 Matsushita Electric Works Ltd 無機質建材の製造方法
JP2732091B2 (ja) 1988-10-31 1998-03-25 キヤノン株式会社 ビデオ信号処理装置
JPH0768137B2 (ja) * 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
JP2949846B2 (ja) * 1990-11-30 1999-09-20 吉富製薬株式会社 アルブミン製剤の保存方法
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
JPH0768137A (ja) 1993-09-02 1995-03-14 Dow Chem Japan Ltd 分離膜モジュール
JPH10265404A (ja) 1996-02-02 1998-10-06 Mitsui Chem Inc ヒト成長ホルモンを含有する医薬製剤
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤

Also Published As

Publication number Publication date
EP1260230A1 (fr) 2002-11-27
JP4683810B2 (ja) 2011-05-18
WO2001064241A1 (fr) 2001-09-07
US20030092622A1 (en) 2003-05-15
US7163671B2 (en) 2007-01-16
EP1260230A4 (fr) 2008-08-06

Similar Documents

Publication Publication Date Title
AU2001236005A1 (en) Preparations stabilized over long time
AU2001294192A1 (en) Solid preparations
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001232799A1 (en) Protein c derivatives
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2001258349A1 (en) Bisacylguanidine
AU8260701A (en) Solution preparations stabilized over long time
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2001258924A1 (en) Microsatellite-aflp
AU2001240791A1 (en) Sequence
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2001288102A1 (en) Solid preparations
AU2001246864A1 (en) Hypotensors
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001236058A1 (en) Preparations for chondrogenesis
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2001256287A1 (en) 2-phenyl-2h-pyridazine-3-ones